The emerging field of chemo- and pharmacoproteomics

Proteomics - Clinical Applications

Volumn 7, Issue 1-2, 2013, Pages 171-180

  Hess, Sonja ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer; Chemoproteomics; Diabetes; Drug interactions; Histone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 MERCAPTOPURINE DERIVATIVE; ACARBOSE; ACETYL COENZYME A; CULLIN; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; ENDOCANNABINOID DEGRADING ENZYME FATTY ACID AMIDE HYDROLASE; ETOPOSIDE; GAMMA SECRETASE; HYDROLASE INHIBITOR; IMATINIB; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NOTCH RECEPTOR; PACLITAXEL; PROTEIN TYROSINE KINASE; RAPAMYCIN; ROSIGLITAZONE; SERINE HYDROLASE RETINOBLASTOMA BINDING PROTEIN 9; SULFONYLUREA; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ACETYLATION; ACTIVITY BASED PROTEIN PROFILING; BINDING SITE; CANCER RESISTANCE; CELL FRACTIONATION; CHEMOPROTEOMICS; DIABETES MELLITUS; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; ENZYME INACTIVATION; FEEDBACK SYSTEM; FUNCTIONAL PROTEOMICS; MALIGNANT NEOPLASTIC DISEASE; PHARMACOLOGICAL PROCEDURES; PHARMACOPROTEOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; UBIQUITINATION;

HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEOME; PROTEOMICS;

EID: 84872745833     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201200091     Document Type: Review

References (103)

1. Olah, M., Rad, R., Ostopovici, L., Bora, A. et al., WOMBAT and WOMBAT-PK: bioactivity databases for lead and drug discovery, in: Schreiber, S. L., Kapoor, T. M., Wess, G. (Eds.), Chemical Biology: From Small Molecules to Systems Biology and Drug Design, Wiley-VCH, Weinheim, Germany 2007, 1-3, pp. 760-786.
2. Mestres, J., Gregori-Puigjane, E., Valverde, S., Sole, R. V., Data completeness-the Achilles heel of drug-target networks. Nat. Biotechnol. 2008, 26, 983-984.
3. Lipinski, C. A., Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
4. Lipinski, C. A., Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov. Today: Technol. 2004, 1, 337-341.
5. Keller, T. H., Pichota, A., Yin, Z., A practical view of "druggability". Curr. Opin. Chem. Biol. 2006, 10, 357-361.
6. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. et al., The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
7. Witzmann, F. A., Grant, R. A., Pharmacoproteomics in drug development. Pharmacogenomics J. 2003, 3, 69-76.
8. Arrell, D. K., Niederlander, N. J., Perez-Terzic, C., Chung, S. et al., Pharmacoproteomics: advancing the efficacy and safety of regenerative therapeutics. Clin. Pharmacol. Ther. 2007, 82, 316-319.
9. Butler, G. S., Overall, C. M., Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry. Curr. Pharm. Des. 2007, 13, 263-270.
10. D'Alessandro, A., Zolla, L., Pharmacoproteomics: a chess game on a protein field. Drug. Discov. Today 2010, 15, 1015-1023.
11. Jain, K. K., Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics 2004, 5, 331-336.
12. Bantscheff, M., Hopf, C., Kruse, U., Drewes, G., Proteomics-based strategies in kinase drug discovery. Ernst Schering Found. Symp. Proc. 2007, 1-28.
13. Barglow, K. T., Cravatt, B. F., Discovering disease-associated enzymes by proteome reactivity profiling. Chem. Biol. 2004, 11, 1523-1531.
14. Harding, M. W., Galat, A., Uehling, D. E., Schreiber, S. L., A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989, 341, 758-760.
15. Rix, U., Superti-Furga, G., Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 2009, 5, 616-624.
16. Miao, Q., Zhang, C. C., Kast, J., Chemical proteomics and its impact on the drug discovery process. Expert Rev. Proteomics 2012, 9, 281-291.
17. Schirle, M., Bantscheff, M., Kuster, B., Mass spectrometry-based proteomics in preclinical drug discovery. Chem. Biol. 2012, 19, 72-84.
18. Moellering, R. E., Cravatt, B. F., How chemoproteomics can enable drug discovery and development. Chem. Biol. 2012, 19, 11-22.
19. Bantscheff, M., Drewes, G., Chemoproteomic approaches to drug target identification and drug profiling. Bioorg. Med. Chem. 2012, 20, 1973-1978.
20. Medvedev, A., Kopylov, A., Buneeva, O., Zgoda, V. et al., Affinity-based proteomic profiling: problems and achievements. Proteomics 2012, 12, 621-637.
21. Eichelbaum, K., Winter, M., Diaz, M. B., Herzig, S. et al., Selective enrichment of newly synthesized proteins for quantitative secretome analysis. Nat. Biotechnol. 2012, 30, 984-990.
22. Adam, G. C., Sorensen, E. J., Cravatt, B. F., Chemical strategies for functional proteomics. Mol. Cell. Proteomics 2002, 1, 781-790.
23. Adam, G. C., Sorensen, E. J., Cravatt, B. F., Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype. Nat. Biotechnol. 2002, 20, 805-809.
24. Adam, G. C., Sorensen, E. J., Cravatt, B. F., Trifunctional chemical probes for the consolidated detection and identification of enzyme activities from complex proteomes. Mol. Cell. Proteomics 2002, 1, 828-835.
25. Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M. et al., Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. USA 2004, 101, 10000-10005.
26. Leung, D., Hardouin, C., Boger, D. L., Cravatt, B. F., Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat. Biotechnol. 2003, 21, 687-691.
27. Speers, A. E., Adam, G. C., Cravatt, B. F., Activity-based protein profiling in vivo using a copper(i)-catalyzed azide-alkyne [3 + 2] cycloaddition. J. Am. Chem. Soc. 2003, 125, 4686-4687.
28. Adibekian, A., Martin, B. R., Wang, C., Hsu, K. L. et al., Click-generated triazole ureas as ultrapotent in vivo-active serine hydrolase inhibitors. Nat. Chem. Biol. 2011, 7, 469-478.
29. Otrubova, K., Boger, D. L., Alpha-ketoheterocycle-based inhibitors of fatty acid amide hydrolase (FAAH). ACS Chem. Neurosci. 2012, 3, 340-348.
30. Bachovchin, D. A., Wolfe, M. R., Masuda, K., Brown, S. J. et al., Oxime esters as selective, covalent inhibitors of the serine hydrolase retinoblastoma-binding protein 9 (RBBP9). Bioorg. Med. Chem. Lett. 2010, 20, 2254-2258.
31. Wong, J. W., McRedmond, J. P., Cagney, G., Activity profiling of platelets by chemical proteomics. Proteomics 2009, 9, 40-50.
32. Zuhl, A. M., Mohr, J. T., Bachovchin, D. A., Niessen, S. et al., Competitive activity-based protein profiling identifies aza-beta-lactams as a versatile chemotype for serine hydrolase inhibition. J. Am. Chem. Soc. 2012, 134, 5068-5071.
33. Weerapana, E., Simon, G. M., Cravatt, B. F., Disparate proteome reactivity profiles of carbon electrophiles. Nat. Chem. Biol. 2008, 4, 405-407.
34. Salisbury, C. M., Cravatt, B. F., Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. J. Am. Chem. Soc. 2008, 130, 2184-2194.
35. Duncan, J. S., Haystead, T. A., Litchfield, D. W., Chemoproteomic characterization of protein kinase inhibitors using immobilized ATP. Methods Mol. Biol. 2012, 795, 119-134.
36. Wright, A. T., Song, J. D., Cravatt, B. F., A suite of activity-based probes for human cytochrome P450 enzymes. J. Am. Chem. Soc. 2009, 131, 10692-10700.
37. Bachovchin, D. A., Cravatt, B. F., The pharmacological landscape and therapeutic potential of serine hydrolases. Nat. Rev. Drug Discov. 2012, 11, 52-68.
38. Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A. et al., Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 2011, 29, 255-265.
39. Patricelli, M. P., Nomanbhoy, T. K., Wu, J., Brown, H. et al., In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 2011, 18, 699-710.
40. Sharma, K., Weber, C., Bairlein, M., Greff, Z. et al., Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 2009, 6, 741-744.
41. Trinkle-Mulcahy, L., Boulon, S., Lam, Y. W., Urcia, R. et al., Identifying specific protein interaction partners using quantitative mass spectrometry and bead proteomes. J. Cell. Biol. 2008, 183, 223-239.
42. Oda, Y., Owa, T., Sato, T., Boucher, B. et al., Quantitative chemical proteomics for identifying candidate drug targets. Anal. Chem. 2003, 75, 2159-2165.
43. Yang, Y., Hahne, H., Kuster, B., Verhelst, S. H., A simple and effective cleavable linker for chemical proteomics applications. Mol. Cell. Proteomics 2012.
44. Shiyama, T., Furuya, M., Yamazaki, A., Terada, T. et al., Design and synthesis of novel hydrophilic spacers for the reduction of nonspecific binding proteins on affinity resins. Bioorg. Med. Chem. 2004, 12, 2831-2841.
45. Scholten, A., Poh, M. K., van Veen, T. A., van Breukelen, B. et al., Analysis of the cGMP/cAMP interactome using a chemical proteomics approach in mammalian heart tissue validates sphingosine kinase type 1-interacting protein as a genuine and highly abundant AKAP. J. Proteome Res. 2006, 5, 1435-1447.
46. von Rechenberg, M., Blake, B. K., Ho, Y. S., Zhen, Y. et al., Ampicillin/penicillin-binding protein interactions as a model drug-target system to optimize affinity pull-down and mass spectrometric strategies for target and pathway identification. Proteomics 2005, 5, 1764-1773.
47. Hahn, R., Berger, E., Pflegerl, K., Jungbauer, A., Directed immobilization of peptide ligands to accessible pore sites by conjugation with a placeholder molecule. Anal. Chem. 2003, 75, 543-548.
48. Ong, S. E., Schenone, M., Margolin, A. A., Li, X. et al., Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc. Natl. Acad. Sci. USA 2009, 106, 4617-4622.
49. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S. et al., Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007, 25, 1035-1044.
50. Chan, N. C., Salazar, A. M., Pham, A. H., Sweredoski, M. J. et al., Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum. Mol. Genet. 2011, 20, 1726-1737.
51. Graham RLJ, S. M., Hess, S., Stable isotope labeling of amino acids in cell culture: an introduction for biologists. Curr. Proteomics 2011, 4, 1-15.
52. Zielinska, D. F., Gnad, F., Wisniewski, J. R., Mann, M., Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell 2010, 141, 897-907.
53. Zhang, H., Li, X. J., Martin, D. B., Aebersold, R., Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat. Biotechnol. 2003, 21, 660-666.
54. Wells, L., Vosseller, K., Cole, R. N., Cronshaw, J. M. et al., Mapping sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational modifications. Mol. Cell. Proteomics 2002, 1, 791-804.
55. Hoffert, J. D., Pisitkun, T., Saeed, F., Song, J. H. et al., Dynamics of the G protein-coupled vasopressin V2 receptor signaling network revealed by quantitative phosphoproteomics. Mol. Cell. Proteomics 2012, 11, M111 014613.
56. Kim, W., Bennett, E. J., Huttlin, E. L., Guo, A. et al., Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol. Cell. 2011, 44, 325-340.
57. Klammer, M., Kaminski, M., Zedler, A., Oppermann, F. et al., Phospho-signature predicts Dasatinib response in non-small cell lung cancer. Mol. Cell. Proteomics 2012, 11, 651-658.
58. Li, J., Rix, U., Fang, B., Bai, Y. et al., A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 2010, 6, 291-299.
59. Pluder, F., Morl, K., Beck-Sickinger, A. G., Proteome analysis to study signal transduction of G protein-coupled receptors. Pharmacol. Ther. 2006, 112, 1-11.
60. Yang, L., Vaitheesvaran, B., Hartil, K., Robinson, A. J. et al., The fasted/fed mouse metabolic acetylome: N6-acetylation differences suggest acetylation coordinates organ-specific fuel switching. J. Proteome Res. 2011, 10, 4134-4149.
61. Ong, S. E., Blagoev, B., Kratchmarova, I., Kristensen, D. B. et al., Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1, 376-386.
62. Fenselau, C., Yao, X., 18O2-labeling in quantitative proteomic strategies: a status report. J. Proteome Res. 2009, 8, 2140-2143.
63. Hajkova, D. C. S. R., Miyagi, K., Masaru, recent technological developments in proteolytic 18O labeling. Curr. Proteomics 2011, 8, 39-46.
64. Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B. et al., Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3, 1154-1169.
65. Britton, L. M., Gonzales-Cope, M., Zee, B. M., Garcia, B. A., Breaking the histone code with quantitative mass spectrometry. Expert. Rev. Proteomics 2011, 8, 631-643.
66. Chen, X., Cushman, S. W., Pannell, L. K., Hess, S., Quantitative proteomic analysis of the secretory proteins from rat adipose cells using a 2D liquid chromatography-MS/MS approach. J. Proteome Res. 2005, 4, 570-577.
67. Chen, X., Hunt, D., Cushman, S. W., Hess, S., Proteomic characterization of thiazolidinedione regulation of obese adipose secretome in Zucker obese rats. Proteomics Clin. Appl. 2009, 3, 1099-1111.
68. Graumann, J., Hubner, N. C., Kim, J. B., Ko, K. et al., Stable isotope labeling by amino acids in cell culture (SILAC) and proteome quantitation of mouse embryonic stem cells to a depth of 5, 111 proteins. Mol. Cell. Proteomics 2008, 7, 672-683.
69. Beck, M., Schmidt, A., Malmstroem, J., Claassen, M. et al., The quantitative proteome of a human cell line. Mol. Syst. Biol. 2011, 7, 549.
70. Nagaraj, N., Kulak, N. A., Cox, J., Neuhauser, N. et al., System-wide perturbation analysis with nearly complete coverage of the yeast proteome by single-shot ultra HPLC runs on a bench top Orbitrap. Mol. Cell. Proteomics 2012, 11, M111 013722.
71. Cox, J., Matic, I., Hilger, M., Nagaraj, N. et al., A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics. Nat. Protoc. 2009, 4, 698-705.
72. Kalli, A., Hess, S., Effect of mass spectrometric parameters on peptide and protein identification rates for shotgun proteomic experiments on an LTQ-orbitrap mass analyzer. Proteomics 2012, 12, 21-31.
73. Graham RLJ, K. A., Smith, GT, Sweredoski, MJ, Hess, S., Tips from the Bench: avoiding pitfalls in proteomics sample preparation. Biomacromol. Mass Spectrom. 2012, 4, 261-272.
74. Graumann, J., Scheltema, R. A., Zhang, Y., Cox, J. et al., A framework for intelligent data acquisition and real-time database searching for shotgun proteomics. Mol. Cell. Proteomics 2012, 11, M111 013185.
75. Heitzler, D., Crepieux, P., Poupon, A., Clement, F. et al., Towards a systems biology approach of-G protein-coupled receptor signalling: challenges and expectations. C. R. Biol. 2009, 332, 947-957.
76. Pluder, F., Sinz, A., Beck-Sickinger, A. G., Proliferative effect of calcitonin gene-related peptide is induced by at least five proteins as identified by proteome profiling. Chem. Biol. Drug Des. 2007, 69, 14-22.
77. Bateman, K. P., Castro-Perez, J., Wrona, M., Shockcor, J. P. et al., MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun. Mass Spectrom. 2007, 21, 1485-1496.
78. Gillet, L. C., Navarro, P., Tate, S., Rost, H. et al., Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell. Proteomics 2012, 11, O111 016717.
79. Geiger, T., Cox, J., Mann, M., Proteomics on an Orbitrap benchtop mass spectrometer using all-ion fragmentation. Mol. Cell. Proteomics 2010, 9, 2252-2261.
80. Picotti, P., Aebersold, R., Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat. Methods 2012, 9, 555-566.
81. Shteynberg, D., Deutsch, E. W., Lam, H., Eng, J. K. et al., iProphet: multi-level integrative analysis of shotgun proteomic data improves peptide and protein identification rates and error estimates. Mol. Cell. Proteomics 2011, 10, M111 007690.
82. Huang da, W., Sherman, B. T., Lempicki, R. A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44-57.
83. Jiao, X., Sherman, B. T., Huang da, W., Stephens, R. et al., DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics 2012, 28, 1805-1806.
84. Boran, A. D., Iyengar, R., Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Dev. 2010, 13, 297-309.
85. Rizzo, P., Osipo, C., Foreman, K., Golde, T. et al., Rational targeting of Notch signaling in cancer. Oncogene 2008, 27, 5124-5131.
86. Rao, S. S., O'Neil, J., Liberator, C. D., Hardwick, J. S. et al., Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res. 2009, 69, 3060-3068.
87. Dar, A. C., Das, T. K., Shokat, K. M., Cagan, R. L., Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 2012, 486, 80-84.
88. Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N. K. et al., SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer. Ther. 2003, 2, 471-478.
89. Fuchs, I. B., Landt, S., Bueler, H., Kuehl, U. et al., Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). Breast Cancer Res. Treat. 2003, 82, 23-28.
90. Wetmore, B. A., Merrick, B. A., Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol. Pathol. 2004, 32, 619-642.
91. Bandara, L. R., Kennedy, S., Toxicoproteomics-a new preclinical tool. Drug Discov. Today 2002, 7, 411-418.
92. Chapal, N., Molina, L., Molina, F., Laplanche, M. et al., Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer. Fundam. Clin. Pharmacol. 2004, 18, 413-422.
93. Edvardsson, U., Alexandersson, M., Brockenhuus von Lowenhielm, H., Nystrom, A. C. et al., A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14, 643. Electrophoresis 1999, 20, 935-942.
94. Edvardsson, U., von Lowenhielm, H. B., Panfilov, O., Nystrom, A. C. et al., Hepatic protein expression of lean mice and obese diabetic mice treated with peroxisome proliferator-activated receptor activators. Proteomics 2003, 3, 468-478.
95. Sanchez, J. C., Converset, V., Nolan, A., Schmid, G. et al., Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice. Proteomics 2003, 3, 1500-1520.
96. Lee, A. Y., Paweletz, C. P., Pollock, R. M., Settlage, R. E. et al., Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry. J. Proteome Res. 2008, 7, 5177-5186.
97. Mackeen, M. M., Kramer, H. B., Chang, K. H., Coleman, M. L. et al., Small-molecule-based inhibition of histone demethylation in cells assessed by quantitative mass spectrometry. J. Proteome Res. 2010, 9, 4082-4092.
98. Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G. et al., Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478, 529-533.
99. Marks, P. A., Xu, W. S., Histone deacetylase inhibitors: potential in cancer therapy. J. Cell. Biochem. 2009, 107, 600-608.
100. Cole, P. A., Chemical probes for histone-modifying enzymes. Nat. Chem. Biol. 2008, 4, 590-597.
101. Spannhoff, A., Sippl, W., Jung, M., Cancer treatment of the future: inhibitors of histone methyltransferases. Int. J. Biochem. Cell. Biol. 2009, 41, 4-11.
102. Young, N. L., DiMaggio, P. A., Plazas-Mayorca, M. D., Baliban, R. C. et al., High throughput characterization of combinatorial histone codes. Mol. Cell. Proteomics 2009, 8, 2266-2284.
103. Raj, L., Ide, T., Gurkar, A. U., Foley, M. et al., Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 2011, 475, 231-234.